Stock SONN SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Market Closed - Nasdaq
Other stock markets
 03:58:48 2024-07-08 pm EDT 		5-day change 1st Jan Change
0.9 USD -1.10% Intraday chart for Sonnet BioTherapeutics Holdings, Inc. -3.23% -48.28%
Jul. 05 Sonnet BioTherapeutics Files Registration for Sale of Up to 5.77 Million Shares by Selling Stockholders MT
Jun. 20 Top Midday Decliners MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sonnet BioTherapeutics Files Registration for Sale of Up to 5.77 Million Shares by Selling Stockholders
MT
Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating
MT
Ladenburg Thalmann Starts Sonnet BioTherapeutics Holdings With Buy Rating, $7 Price Target
MT
EF Hutton Assumes Sonnet BioTherapeutics at Buy With $6.70 Price Target
MT
Chardan Cuts Price Target on Sonnet BioTherapeutics to $12 From $14, Keeps Buy Rating
MT
EF Hutton Assumes Buy Rating on Sonnet BioTherapeutics With $6.70 Price Target
MT
Chardan Lowers Price Target on Sonnet BioTherapeutics to $14 From $17, Keeps Buy Rating
MT
Chardan Cuts Price Target on Sonnet BioTherapeutics to $17 From $22, Anticipating Higher Future Share Count, Maintains Buy Rating
MT
EF Hutton Initiates Coverage on Sonnet BioTherapeutics Holdings at Buy With $6.70 Price Target
MT
Chardan Adjusts Sonnet BioTherapeutics Holdings Price Target to $22 From $2, Maintains Buy Rating
MT
Chardan Trims Sonnet BioTherapeutics Holdings' Price Target to $2 From $2.50, Maintains Buy Rating
MT
BTIG Adjusts Price Target on Sonnet BioTherapeutics Holdings to $2 From $5, Reiterates Buy Rating
MT
Chardan Capital Adjusts Sonnet BioTherapeutics Holdings PT to $2.50 From $8, Maintains Buy Rating
MT
HC Wainwright Initiates Coverage on Sonnet BioTherapeutics Holdings With Buy Rating, $2 Price Target
MT
SONNET BIOTHERAPEUTICS : BTIG Starts Sonnet BioTherapeutics Holdings at Buy with $5 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SONN Stock
  4. News Sonnet BioTherapeutics Holdings, Inc.
  5. Analyst Reco.